- KRAS mutations in non-small cell lung cancer and options of treatment2020 | First Faculty of Medicine
- G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Monitoring of KRAS mutation during cetuximab treatment of head and neck squamous cell carcinoma2012 | First Faculty of Medicine
- KRAS mutation assay on EUS-FNA specimens from pacients with pancreatic mass2016 | First Faculty of Medicine, Central Library of Charles University
- Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors2010 | Central Library of Charles University
- KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control study2016 | First Faculty of Medicine
- Circulating tumour-derived KRAS mutations in pancreatic cancer cases are predominantly carried by very short fragments of cell-free DNA2020 | First Faculty of Medicine
- Extraordinary response to erlotinib therapy in a patient with lung adenocarcinoma exhibiting KRAS mutation and EGFR amplification2011 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Impact of EGFR and KRAS mutations on survival prognosis of NSCLC patients treated with tyrosine-kinase inhibitors: Comparison of gefitinib and erlotinib.2009 | Central Library of Charles University
- Impact of EGFR and KRAS mutations on survival prognosis of NSCLC patients treated with tyrosine-kinase inhibitors: Comparison of gefitinib and erlotinib.2009 | Faculty of Medicine in Pilsen
- The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer2013 | Faculty of Medicine in Pilsen
- Whole genome amplification induced bias in the detection of KRAS-mutated cell populations during colorectal carcinoma tissue testing2015 | Second Faculty of Medicine
- The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy2016 | Faculty of Medicine in Pilsen
- Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome2017 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
- KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma2011 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma2011 | First Faculty of Medicine
- Recurrent KRAS mutations are early events in the development of papillary renal neoplasm with reverse polarity2022 | Faculty of Medicine in Pilsen
- Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors2010 | Faculty of Medicine in Pilsen
- Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: Their relationship to KRAS mutational status and disease recurrence2011 | Second Faculty of Medicine
- Dominance of EGFR and insignificant KRAS mutations in prediction of Tyrosin-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status2009 | Central Library of Charles University
- Dominance of EGFR and insignificant KRAS mutations in prediction of Tyrosin-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status2009 | Faculty of Medicine in Pilsen
- Dominance of EGFR and insignificant KRAS mutations in prediction of Tyrosin-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status2009 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases2020 | Faculty of Medicine in Pilsen
- KRAS (G12S) mutation in a patient with NSCLC treated with erlotinib – a case report2013 | Faculty of Medicine in Pilsen
- Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation2015 | Faculty of Medicine in Pilsen, Faculty of Science
- Impact of EGFR and KRAS mutations on survival prognosis of NSCLC patients treated with tyrosine-kinase inhibitors: Comparison of gefitinib and erlotinib.2009 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe2010 | First Faculty of Medicine
- Molecular pathology of cholangiocellular carcinomas2019 | First Faculty of Medicine, Third Faculty of Medicine
- Combining ultrasound-guided fnac with elastography improves the sensitivity and specificity in pre-operative diagnostics of thyroid nodules and prediction of molecular markers expression?2014 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
- The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma2018 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen